A phase II study of days 1 and 8 combination of docetaxel plus gemcitabine for the second-line treatment of patients with advanced non-small-cell lung cancer and good performance status

Lung Cancer

Volumn 56, Issue 2, 2007, Pages 255-262

  Cobo, Manuel ^a   Gutiérrez, Vanesa ^a   Alcaide, Julia ^a   Alés, Inmaculada ^a   Villar, Esther ^a   Gil, Silvia ^a   Durán, Gema ^a   Martínez, Joaquina ^a   Carabantes, Francisco ^a   Bretón, Juan J ^a   Benavides, Manuel ^a  

^a HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

Author keywords

Docetaxel; Gemcitabine; Non small cell lung cancer; Second line

Indexed keywords

DEXAMETHASONE; DOCETAXEL; GEMCITABINE; PLATINUM DERIVATIVE;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; ARTICLE; ASTHENIA; BONE MARROW; CARDIOTOXICITY; CLINICAL ASSESSMENT; CLINICAL ASSESSMENT TOOL; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; EASTERN COOPERATIVE ONCOLOGY GROUP PERFORMANCE STATUS; FEBRILE NEUTROPENIA; FEMALE; FEVER; FOLLOW UP; HISTOPATHOLOGY; HUMAN; INFECTION; LARGE CELL CARCINOMA; LUNG ADENOCARCINOMA; LUNG ALVEOLUS CELL CARCINOMA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUTROPENIA; PATIENT SELECTION; PERFORMANCE MEASUREMENT SYSTEM; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RATING SCALE; SOMATOSENSORY DISORDER; SQUAMOUS CELL CARCINOMA; SURVIVAL TIME; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT OUTCOME; TREATMENT RESPONSE; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; DEOXYCYTIDINE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; SURVIVAL ANALYSIS; SURVIVAL RATE; TAXOIDS;

EID: 34247097395     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2006.12.013     Document Type: Article

References (43)

1. Bunn Jr. P.A., and Kelly K. New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: a review of the literature and future directions. Clin Cancer Res 5 (1998) 1087-1100
2. Grilli R., Oxman A.D., and Julian J.M. Chemotherapy is for advanced non-small cell lung cancer. How much benefit is enough?. J Clin Oncol 11 (1993) 1866-1872
3. Non Small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials. Br Med J 311 (1955) 899-909
4. D'Addario G., Pintilie M., Leighl N.B., Feld R., Cerny T., Shepherd F.A., et al. Platinum-based versus non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a meta-analysis of the published literature. J Clin Oncol 23 (2005) 2926-2936
5. Spiridonidis C.H., Laufman L.R., Jones J., Rhodes V.A., Wallace K., and Nicol S. Phase I study of docetaxel dose escalation in combination with fixed weekly gemcitabine in patients with advanced malignancies. J Clin Oncol 16 (1998) 3866-3873
6. Georgoulias V., Kouroussis C., Androulakis N., Kakolyris S., Dimopoulos M.A., Papadakis E., et al. Front-line treatment of advanced non small cell lung cancer with docetaxel and gemcitabine: a multicenter phase II trial. J Clin Oncol 17 (1999) 914-920
7. Denes A., Needles B., Schmidt A., White L., Greco A., and Eckardt J. A comparison of two schedules of docetaxel (D) in combination with gemcitabine (G) given every other week. Proc Am Soc Clin Oncol 19 (2000) 212a [abstract 828]
8. Rizvi N.A., Spiridonidis H., Davis T.H., Bhargava P., Marshall J.L., Dahut W., et al. Docetaxel and gemcitabine combinations in non small cell lung cancer. Semin Oncol 26 Suppl 16 (1999) S27-S31
9. Rubio G., Blajman C., Capo A., Cazap E., Chacon R., Freue M., et al. Docetaxel and gemcitabine in metastatic non small cell lung cancer (NSCLC). A phase II study. Preliminary feasibility report. Proc Am Soc Clin Oncol 11 (1999) 522a [abstract 2012]
10. Rebattu P., Quantin X., Morere J.F., Azarian M.R., Khial F., Dumortier A., et al. A phase II study of docetaxel (D) and gemcitabine (G) combination in patients (pts) with non small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 19 (2000) 539a [abstract 2124]
11. Hirsh V., Whittomb R., Desjardinsc P., Laberge F., Latreille J., Samson B., et al. Docetaxel and gemcitabine administered on days 1 and 8 for metastatic non-small cell lung carcinoma (NSCLC): a phase II multicenter trial. Lung Cancer 46 (2004) 113-118
12. Neubauer M.A., Garfield D.H., Kuerfler P.R., Raju R.N., Lindquist D.L., Soo E.W., et al. Results of a phase II multicenter trial of weekly docetaxel and gemcitabine as first-line therapy for patients with advanced non-small cell lung cancer. Lung Cancer 46 (2004) 113-118
13. Georgoulias V., Papadakis E., Alexopoulos A., Tsiafaki X., Rapti A., Veslemes M., et al. Platinum-based and non-platinum based chemotherapy in advanced non small cell lung cancer: a randomized multicentre trial. Lancet 357 (2001) 1478-1484
14. Solomon B., and Bunn Jr. P.A. Gemcitabine plus docetaxel for advanced or metastatic non-small cell lung cancer: similar survival to cisplatin plus vinorelbine and less toxicity. Cancer Treat Rev 31 (2005) 571-576
15. Pujol J.L., Breton J.L., Gervais R., Rebattu P., Depierre A., Morère J.F., et al. Gemcitabine-docetaxel versus cisplatin-vinorelbine in advanced or metastatic non-small-cell lung cancer: a phase III study addressing the case for cisplatin. Ann Oncol 16 (2005) 602-610
16. Georgulias V., Ardavanis A., Tsiafaki X., Agelidou A., Mixalopoulou P., Anagnostopoulou O., et al. Vinorelbine plus cisplatin versus docetaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III randomized trial. J Clin Oncol 23 (2005) 2882-2883
17. Rigas J., Dragnev K., Kerry M., Cole B., Evans A., Page R., et al. Survival equivalence of non-platinum based and platinum based chemotherapy for advanced non-small cell lung cancer (NSCLC): the results of a multicenter internet-based phase III randomized study. Lung Cancer 49 Suppl 2 (2005) s35 [abstract 0-098]
18. Olszanski A.J., and Rigas J. Docetaxel and gemcitabine: a nonplatinum combination for non-small cell lung cancer. Clin Lung Cancer 1 Suppl 1 (2000) s15-s19
19. Shepherd F., Dancey J., Ramlau R., Mattson K., Gralla R., O'Rourke M., et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non small-cell lung cancer previously treated with cisplatin based chemotherapy. J Clin Oncol 18 (2000) 2095-2103
20. Shepherd F.A., Pereira J.R., Ciuleanu T., Tan E.H., Hirsh V., Thongprasert S., et al. Erlotinib in previously treated non-small-cell lung cancer. New Engl J Med 353 (2005) 123-132
21. Fossella F.V., De Vore R., Kerr R., Crawford J., Natale R.R., Dunphy F., et al. Randomized phase III trial of docetaxel vs vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. J Clin Oncol 18 (2000) 2354-2362
22. Spironidis C.H. Second-line chemotherapy for non-small cell lung cancer with monthly docetaxel and weekly gemcitabine: a phase II trial. Ann Oncol 12 (2001) 89-94
23. Kosmas C., Tsavaris N., Vadiaka M., Stavroyianni N., Koutras A., Malamos N., et al. Gemcitabine and docetaxel as second-line chemotherapy for patients with nonsmall cell lung carcinoma who fail prior paclitaxel plus platinum-based regimens. Cancer 92 (2001) 2902-2910
24. Kakolyris S., Papadakis E., Tsiafaki X., Kalofonos C., Rapti A., Toubis M., et al. Docetaxel in combination with gemcitabine plus rhG-CSF support as second-line treatment in non small cell lung cancer. A multicenter phase II study. Lung Cancer 32 (2001) 179-187
25. Hainsworth J.D., Burris H.A., Billings F.T., Bradof J.E., Baker M., and Greco F.A. Weekly docetaxel with either gemcitabine or vinorelbine second-line treatment in patients with advanced non-small cell lung carcinoma. Cancer 92 (2001) 2391-2398
26. Chen Y.M., Perng R.P., Lin W.C., Wu H.W., Tsai C.M., Whang-Peng J., et al. Phase II study of docetaxel and gemcitabine combination chemotherapy in non-small-cell lung cancer patients failing previous chemotherapy. Am J Clin Oncol 25 (2002) 509-512
27. Niho S., Kubota K., Goto K., Ohmatsu H., Matsumoto T., Kakinuma R., et al. Combination second-line chemotherapy with gemcitabine and docetaxel for recurrent non-small-cell lung cancer after platinum-containing chemotherapy: a phase I/II trial. Cancer Chemother Pharmacol 52 (2003) 19-24
28. Tas F., Demir C., Camlica H., Ustuner Z., and Tupuz E. Second-line docetaxel and gemcitabine combination chemotherapy in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy: a phase II trial. Med Oncol 21 (2004) 233-240
29. Kosmas C., Tsavaris N., Mylonakis N., and Kalofonos H.P. An overview of current results with the gemcitabine and docetaxel combination as initial and salvage chemotherapy regimen in advanced non-small cell lung cancer. Crit Rev Oncol Hematol 45 (2003) 265-275
30. Gehan E.A., and Tefft M.C. Will there be resistance to the RECIST (Response Evaluation Criteria in Solid Tumors)?. J Natl Cancer Inst 92 (2000) 179-181
31. Patel R., Keiser L.W., Justice G.R., Quan E., George S., Escamilla L., et al. ACORN 9901: a multicenter randomized trial of docetaxel and gemcitabine versus weekly paclitaxel and gemcitabine in patients (pts) with non small cell lung cancer. Proc Am Soc Clin Oncol 21 (2002) 320a [abstract 1276]
32. Gillenwater H.H., Tynan M., Natoli S., Schell M.J., and Socinski M.A. Second-line gemcitabine in refractory stage IV non small-cell lung cancer: a phase II trial. Clin Lung Cancer 2 (2000) 133-138
33. Crino L., Mosconi A.M., Scagliotti G., Selvaggi G., Novello S., Rinaldi M., et al. Gemcitabine as second-line treatment for advanced non-small cell lung cancer: a phase II study. J Clin Oncol 17 (1999) 2081-2085
34. Gridelli C., Gallo C., Di Maio M., Barletta E., Illiano A., Maione P., et al. A randomized clinical trial of two docetaxel regimens (weekly vs 3 week) in the second-line treatment of non-small-cell lung cancer. The DISTAL 01 study. Br J Cancer 91 (2004) 1996-2004
35. Gervais R., Ducolone A., Breton J.L., Braun D., Lebeau B., Vaylet F., et al. Phase II randomized trial comparing docetaxel given every 3 weeks with weekly schedule as second-line therapy in patients with advanced non-small-cell lung cancer (NSCLC). Ann Oncol 16 (2005) 90-96
36. Schuette W., Nagel S., Blankenburg T., Lautenschlaeger C., Hans K., Schmidt E.W., et al. Phase III study of second-line chemotherapy for advanced non-small-cell lung cancer with weekly compared with 3-weekly docetaxel. J Clin Oncol 23 (2005) 8389-8395
37. Camps C., Massuti B., Jimenez A., Maeste I., García Gómez R., Isla D., et al. Randomized phase III study of 3-weekly versus weekly docetaxel in pretreated advanced non-small-cell lung cancer: a Spanish Lung Cancer Group trial. Ann Oncol 17 (2006) 467-472
38. Pfister D.G., Johnson D.H., Azzoli C.G., Sause W., Smith T.J., Baker S., et al. American Society of clinical Oncology treatment for unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol 22 (2004) 330-353
39. Hanna N., Shepherd F.A., Fossella F.V., Pereira J.R., De Marinis F., von Pawel J., et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 22 (2004) 1589-1597
40. Spiridonis C.H., and Laufman L.R. Docetaxel and gemcitabine combinations in chemotherapy-pretreated non-small cell lung cancer. Clin Lung Cancer 1 Suppl 1 (2000) s20-s23
41. Georgoulias V., Kouroussis C., Agelidou A., Boukovinas I., Palamidas P., Stavrinidis E., et al. Irinotecan plus gemcitabine vs irinotecan for the second-line treatment of patients with advanced non-small-cell lung cancer pretreated with docetaxel and cisplatin: a multicentre, randomized, phase II study. Br J Cancer 91 (2004) 482-488
42. Wachters F.M., Groen H.J., Biesma B., Schramel F.M., Postmus P.E., Stigt J.A., et al. A randomized phase II trial of docetaxel vs docetaxel and irinotecan in patients with stage IIIb-IV non-small-cell lung cancer who failed first-line treatment. Br J Cancer 92 (2005) 15-20
43. Pectasides D., Pectasides M., Farmakis D., Kostopoulou V., Nikolaou M., Gaglia A., et al. Comparison of docetaxel and docetaxel-irinotecan combination as second-line chemotherapy in advanced non-small-cell lung cancer: a randomized phase II trial. Ann Oncol 16 (2005) 294-299